$ATRA
Atara Biotherapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023057147 Filed on November 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $4.252M $2.138M $4.459M
YoY Change 1823.98% -52.05% -16.96%
Cost Of Revenue $3.160M $2.620M
YoY Change
Gross Profit $1.092M -$480.0K
YoY Change
Gross Profit Margin 25.68% -22.45%
Selling, General & Admin $10.39M $12.25M $15.74M
YoY Change -20.12% -22.19% -20.68%
% of Gross Profit 951.28%
Research & Development $43.98M $56.89M $70.16M
YoY Change -29.83% -18.91% -0.25%
% of Gross Profit 4027.56%
Depreciation & Amortization $1.209M $900.0K $1.369M
YoY Change -3.67% -34.26% -40.91%
% of Gross Profit 110.71%
Operating Expenses $54.37M $56.89M $89.08M
YoY Change -28.17% -36.14% -1.22%
Operating Profit -$53.28M -$69.61M -$84.62M
YoY Change -17.74% -0.22%
Interest Expense -$465.0K $1.395M $541.0K
YoY Change -147.99% 157.86% 265.54%
% of Operating Profit
Other Income/Expense, Net -$12.00K -$27.00K $541.0K
YoY Change -104.99% 265.54%
Pretax Income -$60.44M -$69.82M -$84.08M
YoY Change -18.95% -16.97% -0.69%
Income Tax $11.00K -$19.00K $10.00K
% Of Pretax Income
Net Earnings -$60.45M -$69.80M -$84.09M
YoY Change -18.94% -17.0% -0.68%
Net Earnings / Revenue -1421.68% -3264.59% -1885.87%
Basic Earnings Per Share -$0.66 -$0.82
Diluted Earnings Per Share -$0.56 -$0.66 -$0.82
COMMON SHARES
Basic Shares Outstanding 101.9M 101.1M 94.36M
Diluted Shares Outstanding 106.4M 102.4M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.73M $102.4M $265.4M
YoY Change -78.7% -61.42% -25.71%
Cash & Equivalents $25.84M $64.79M $65.11M
Short-Term Investments $25.88M $37.60M $200.3M
Other Short-Term Assets $6.330M $9.388M $17.39M
YoY Change -38.59% -46.02% 41.96%
Inventory $9.706M $6.591M
Prepaid Expenses
Receivables $34.11M $163.0K $249.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $101.9M $118.7M $283.0M
YoY Change -65.48% -58.06% -23.4%
LONG-TERM ASSETS
Property, Plant & Equipment $58.79M $4.628M $7.270M
YoY Change -20.9% -36.34% -86.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.844M $6.289M $7.166M
YoY Change -30.98% -12.24% 283.21%
Total Long-Term Assets $63.64M $70.09M $85.27M
YoY Change -21.77% -17.8% 6.02%
TOTAL ASSETS
Total Short-Term Assets $101.9M $118.7M $283.0M
Total Long-Term Assets $63.64M $70.09M $85.27M
Total Assets $165.5M $188.8M $368.3M
YoY Change -56.03% -48.74% -18.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.684M $6.511M $11.30M
YoY Change -46.38% -42.36% -31.72%
Accrued Expenses $59.79M $8.299M $46.50M
YoY Change -5.41% -82.15% 59.71%
Deferred Revenue $77.83M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $915.0K $900.0K $837.0K
YoY Change 9.71% 7.53%
Total Short-Term Liabilities $142.2M $79.09M $72.24M
YoY Change 80.22% 9.47% -16.14%
LONG-TERM LIABILITIES
Long-Term Debt $34.65M $0.00 $3.762M
YoY Change 851.19% -100.0%
Other Long-Term Liabilities $87.86M $4.848M $5.549M
YoY Change -47.46% -12.63% -89.65%
Total Long-Term Liabilities $122.5M $4.848M $5.549M
YoY Change -28.3% -12.63% -89.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $142.2M $79.09M $72.24M
Total Long-Term Liabilities $122.5M $4.848M $5.549M
Total Liabilities $264.7M $239.6M $181.2M
YoY Change 5.99% 32.24% 29.63%
SHAREHOLDERS EQUITY
Retained Earnings -$1.969B -$1.909B -$1.618B
YoY Change 16.31% 17.93%
Common Stock $1.870B $1.858B $1.809B
YoY Change 2.66% 2.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$99.23M -$50.84M $187.1M
YoY Change
Total Liabilities & Shareholders Equity $165.5M $188.8M $368.3M
YoY Change -56.03% -48.74% -18.14%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$60.45M -$69.80M -$84.09M
YoY Change -18.94% -17.0% -0.68%
Depreciation, Depletion And Amortization $1.209M $900.0K $1.369M
YoY Change -3.67% -34.26% -40.91%
Cash From Operating Activities -$50.41M -$51.34M -$65.06M
YoY Change -11.38% -21.08% 10.31%
INVESTING ACTIVITIES
Capital Expenditures $43.00K $280.0K -$132.0K
YoY Change 16.22% -312.12% -96.58%
Acquisitions
YoY Change
Other Investing Activities $9.989M $70.73M $59.83M
YoY Change -80.51% 18.22% 1084.73%
Cash From Investing Activities $9.946M $70.44M $59.70M
YoY Change -80.58% 18.0% 4899.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.510M -210.0K -214.0K
YoY Change -95.32% -1.87% -100.45%
NET CHANGE
Cash From Operating Activities -50.41M -51.34M -65.06M
Cash From Investing Activities 9.946M 70.44M 59.70M
Cash From Financing Activities 1.510M -210.0K -214.0K
Net Change In Cash -38.95M 18.89M -5.574M
YoY Change -246.28% -438.89% -47.65%
FREE CASH FLOW
Cash From Operating Activities -$50.41M -$51.34M -$65.06M
Capital Expenditures $43.00K $280.0K -$132.0K
Free Cash Flow -$50.45M -$51.62M -$64.93M
YoY Change -11.36% -20.49% 17.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001604464
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36548
dei Entity Registrant Name
EntityRegistrantName
ATARA BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0920988
dei Entity Address Address Line1
EntityAddressAddressLine1
2380 Conejo Spectrum Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Thousand Oaks
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91320
dei City Area Code
CityAreaCode
805
dei Local Phone Number
LocalPhoneNumber
623-4211
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ATRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101922250
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64791000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
37617000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
149877000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
163000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40221000
CY2023Q3 us-gaap Inventory Net
InventoryNet
6591000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9388000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10308000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
118696000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
295080000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4628000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59175000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68022000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6289000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7018000
CY2023Q3 us-gaap Assets
Assets
188788000
CY2022Q4 us-gaap Assets
Assets
376420000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6511000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6871000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14430000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17659000
CY2023Q3 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
23968000
CY2022Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24992000
CY2023Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
11611000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
8000000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22569000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
79089000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78916000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
73929000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77000000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48508000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58064000
CY2023Q3 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
33252000
CY2022Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
30236000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4848000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5564000
CY2023Q3 us-gaap Liabilities
Liabilities
239626000
CY2022Q4 us-gaap Liabilities
Liabilities
249780000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101922000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101922000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95927000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95927000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1858423000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1821721000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-571000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2067000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1908700000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1693024000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-50838000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
atra Other Non Cash Items Net
OtherNonCashItemsNet
148000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
188788000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
376420000
CY2023Q3 atra Commercialization Revenue
CommercializationRevenue
2020000
CY2022Q3 atra Commercialization Revenue
CommercializationRevenue
0
atra Commercialization Revenue
CommercializationRevenue
3697000
atra Commercialization Revenue
CommercializationRevenue
0
CY2023Q3 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
118000
CY2022Q3 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
4459000
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
624000
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
63352000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2138000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4459000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4321000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
63352000
CY2023Q3 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
2615000
CY2022Q3 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
0
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
5726000
atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
0
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56888000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70157000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175185000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
210018000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12247000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18924000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39454000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58308000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
71750000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
89081000
us-gaap Costs And Expenses
CostsAndExpenses
220365000
us-gaap Costs And Expenses
CostsAndExpenses
268326000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-69612000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-84622000
us-gaap Operating Income Loss
OperatingIncomeLoss
-216044000
us-gaap Operating Income Loss
OperatingIncomeLoss
-204974000
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
1218000
CY2022Q3 us-gaap Interest Income Operating
InterestIncomeOperating
973000
us-gaap Interest Income Operating
InterestIncomeOperating
4715000
us-gaap Interest Income Operating
InterestIncomeOperating
1904000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1395000
CY2022Q3 us-gaap Interest Expense
InterestExpense
123000
us-gaap Interest Expense
InterestExpense
4109000
us-gaap Interest Expense
InterestExpense
256000
CY2023Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
CY2022Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
50237000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-309000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-234000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-631000
CY2023Q3 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
204000
CY2022Q3 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
541000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
372000
atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
51254000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69816000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-84081000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-215672000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-153720000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-69797000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84091000
us-gaap Net Income Loss
NetIncomeLoss
-215676000
us-gaap Net Income Loss
NetIncomeLoss
-153730000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
362000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-341000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1496000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2591000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69435000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84432000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-214180000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-156321000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106401000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106401000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102423000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102423000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105163000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105163000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101590000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101590000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
590000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
93000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11764000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-74771000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
830000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64960000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1000
CY2023Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
747000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12552000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-71108000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
304000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7454000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11143000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-69797000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
362000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-50838000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279614000
CY2022Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
20516000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
616000
CY2022Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
96000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14335000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1524000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
224316000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
3000
CY2022Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1309000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14117000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
18466000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-726000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
257479000
CY2022Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
4000
CY2022Q3 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
47000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14023000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84091000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-341000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
187113000
us-gaap Profit Loss
ProfitLoss
-215676000
us-gaap Profit Loss
ProfitLoss
-153730000
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
50237000
us-gaap Share Based Compensation
ShareBasedCompensation
35459000
us-gaap Share Based Compensation
ShareBasedCompensation
42475000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3624000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4398000
us-gaap Accretion Expense
AccretionExpense
3729000
us-gaap Accretion Expense
AccretionExpense
0
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1320000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-974000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
8847000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
6103000
atra Other Non Cash Items Net
OtherNonCashItemsNet
70000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-40058000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-737000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5005000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
-920000
atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
3903000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
119000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
139000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-319000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4760000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3229000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7545000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-1024000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
4417000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
607000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5595000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
540000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-51468000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-9953000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-6781000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
142000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
244000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142571000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-213550000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
83647000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
181164000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
198723000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
242293000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1179000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4156000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
94765000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113922000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
151738000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
590000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20516000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
747000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1452000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
94000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
623000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
732000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
396000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-13000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-155000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
498000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20794000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28151000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-41018000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107478000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64937000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66460000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
35000
us-gaap Interest Paid Net
InterestPaidNet
332000
us-gaap Interest Paid Net
InterestPaidNet
256000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
100000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, accrued research and development expenses, stock-based compensation expense, income taxes and the liability related to the sale of future revenues. Actual results could differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101169000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
239069000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21217662
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19135516
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21217662
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19135516
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
97367000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
96863000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
202323000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
201359000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
4373000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
4306000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
36746000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
35643000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
101740000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
237002000
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
400000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
800000
CY2023Q3 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2022Q3 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64791000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64937000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
3000000
CY2022Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
30236000
us-gaap Accretion Expense
AccretionExpense
3729000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
61000
us-gaap Payments For Royalties
PaymentsForRoyalties
11000
CY2023Q3 atra Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
34015000
CY2023Q3 atra Liability Related To The Sale Of Future Revenue Current
LiabilityRelatedToTheSaleOfFutureRevenueCurrent
-763000
CY2023Q3 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
33252000
CY2022Q3 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.20
CY2022Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6000000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
5890000
us-gaap Restructuring Charges
RestructuringCharges
45000
us-gaap Restructuring Charges
RestructuringCharges
5890000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1545000
us-gaap Restructuring Charges
RestructuringCharges
45000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1513000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
77000
CY2023Q3 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2022Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2022Q2 atra Supply Agreement Maximum Extension Term
SupplyAgreementMaximumExtensionTerm
P10Y
CY2023Q3 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2022Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q3 atra Minimum Commitments Expense
MinimumCommitmentsExpense
800000
atra Minimum Commitments Expense
MinimumCommitmentsExpense
16100000
CY2023Q3 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
11000000
CY2022Q4 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
9200000
CY2023Q3 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2022Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2023Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2022Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 atra Common Stock Value Remained Available To Be Sold
CommonStockValueRemainedAvailableToBeSold
55200000
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
26744333
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11143000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14023000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35459000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42475000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2422000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1214000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
4169000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
372000
CY2023Q3 us-gaap Inventory Net
InventoryNet
6591000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19613000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18722000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14985000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12422000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4628000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023Q3 us-gaap Depreciation
Depreciation
900000
CY2022Q3 us-gaap Depreciation
Depreciation
1100000
us-gaap Depreciation
Depreciation
2800000
us-gaap Depreciation
Depreciation
3800000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8299000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7435000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12409000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12806000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
887000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
834000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
763000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
211000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
319000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22569000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000

Files In Submission

Name View Source Status
0000950170-23-057147-index-headers.html Edgar Link pending
0000950170-23-057147-index.html Edgar Link pending
0000950170-23-057147.txt Edgar Link pending
0000950170-23-057147-xbrl.zip Edgar Link pending
atra-20230930.htm Edgar Link pending
atra-20230930.xsd Edgar Link pending
atra-ex10_1.htm Edgar Link pending
atra-ex10_2.htm Edgar Link pending
atra-ex31_1.htm Edgar Link pending
atra-ex31_2.htm Edgar Link pending
atra-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
atra-20230930_def.xml Edgar Link unprocessable
atra-20230930_cal.xml Edgar Link unprocessable
atra-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atra-20230930_lab.xml Edgar Link unprocessable
atra-20230930_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending